TA-HPV data

CNTBY and collaborators published in The Lancet results of an open label Phase I/II trial in 8 late-stage cervical cancer patients. Patients in the U.K. study were vaccinated with a single dose of TA-HPV immunotherapy. Each patient mounted an anti-vaccinia antibody response and 3 of 8 developed an HPV-specific antibody response. HPV-specific cytotoxic T lymphocytes, the effector mechanism most likely to be of therapeutic benefit, were detected in 1 of 3 evaluable patients. ...